Published in Nat Rev Drug Discov on March 11, 2016
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 0.97
Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov (2016) 0.88
Deep tissue imaging: a review from a preclinical cancer research perspective. Histochem Cell Biol (2016) 0.84
Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol (2017) 0.83
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res (2017) 0.80
[The pathology of adverse events with immune checkpoint inhibitors]. Pathologe (2017) 0.78
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends Biotechnol (2016) 0.78
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer (2017) 0.77
Future perspectives in cancer immunotherapy. Ann Transl Med (2016) 0.77
IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens. Oncotarget (2016) 0.76
Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75
The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4(+) T-cell-mediated antitumor memory immune response. Cell Death Dis (2017) 0.75
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov (2017) 0.75
miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget (2016) 0.75
The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. Oncoimmunology (2017) 0.75
The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. Cancers (Basel) (2016) 0.75
Overview of advances in cancer immunotherapy. Ann Transl Med (2016) 0.75
[Basic principles: signaling pathways and checkpoints]. Radiologe (2017) 0.75
Immunology: Mind the immuno-connection gap. Nat Chem Biol (2017) 0.75
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Mol Ther (2017) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Signatures of mutational processes in human cancer. Nature (2013) 21.63
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Cancer immunotherapy comes of age. Nature (2011) 12.35
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet (2015) 8.12
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol (2014) 4.37
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29
A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (2014) 3.90
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
The chemokine superfamily revisited. Immunity (2012) 2.83
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2014) 2.40
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
The cancer vaccine roller coaster. Nat Biotechnol (2009) 2.26
II. Contribution to the Knowledge of Sarcoma. Ann Surg (1891) 2.21
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol (2014) 2.03
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol (2015) 1.66
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 1.58
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol (2013) 1.55
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev (2015) 1.53
Bispecific antibodies. Drug Discov Today (2015) 1.44
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res (2015) 1.41
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother (2013) 1.30
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26
NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol Res (2015) 1.25
Designing tomorrow's vaccines. N Engl J Med (2013) 1.21
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
Evolution of end points for cancer immunotherapy trials. Ann Oncol (2012) 1.10